CRISPincette™ Lung
Lung cancer diagnostic kit using ultra-precision CRISPR genetic scissors
CRISPincette™ Lung is GeneCker’s new non-small cell lung cancer (NSCLC) diagnostic panel that can diagnose cancer with a small amount of blood by applying the ultra-precision CRISPR/Cas9 system to improve the detection limit of genetic variation.
Liquid biopsy to diagnose cancer genes using blood
Lung cancer genes can be analyzed quickly and accurately by collecting blood instead of a complicated surgical method. Periodic monitoring is also possible with a simple procedure.
Introduction
Cell-free DNA preparation & PCR enrichment
CRISPincette™ is a liquid biopsy diagnostic kit panel. It extracts cell-free DNA (cfDNA) using various DNA extraction kits. The extracted cell-free DNA (higher than recommended quality) should be amplified with PCR to obtain sufficient amounts of the target site.
gcCas9 Digestion
GeneCker’s ultra-precision CRISPR genetic scissors (gcCas9) technology is applied to the panel. gcCas9 is a tool for detecting cancer cell-derived mutant genes present in the blood. It specifically cuts only normal genes and not affects target cancer genes. After the experimental process, only the target cancer gene is detected.
Next Generation Sequencing (NGS) & Analysis
Target cancer genes not cut by gcCas9 can be amplified again through PCR equipment. The amplified target cancer gene is generated by the NGS sequencing equipment with CRISPincette™ panel data. The generated data can be analyzed through our in-house database analysis program.
Performance
High analytical sensitivity
Cancer cells in blood rarely exist in a very low proportion, making them difficult to analyze. CRISPincette™ Lung panel is equipped with GeneCker’s ultra-precision CRISPR gene scissors (gcCas9), so it is possible to detect low-frequency mutations.
Cost-effectiveness
CRISPincette™ Lung panel with high analytical sensitivity can identify various genetic mutations with a single blood sample.
We selected essential gene regions for diagnosis and excluded unnecessary normal gene regions. The number of NGS analysis samples has significantly increased compared to the existing panel.
Product Specification
| CRISPincette™ Lung | ||
|---|---|---|
| Input DNA | cell-free DNA | |
| Target enrichment | PCR amplicon-based | |
| Platform | Illumina MiSeqDx | |
| Target Size | 760 bp Main hotspot 10 |
|
| Applications | Indel, SNV | |
| Library prep time | ≤ 5 hr | |
| Analysis solution | PinAnalysis™ | |
| Target Hotspot List | |
|---|---|
| EGFR E746_A750del | BRAF L618W |
| EGFR T790 | BRAF V600E |
| EGFR L858R | NRAS G12D |
| EGFR C797S | KRAS G12D |
| MET_exon14 skipping (Left & Right) | |
Performance evaluation
| Total Specification | |||
|---|---|---|---|
| Sensitivity | 97% | ||
| Specificity | 91% | ||
| Accuracy | PPA | 97% | (Positive Percentage Agreement) |
| PPV | 94% | (Positive Predictive Value) | |
| LOD | Between 0.25% and 0.5% VAF |
(Limit Of Detection) | |
| Specific variants | EGFR | KRAS |
|---|---|---|
| Sensitivity | 96% | 96% |
| Specificity | 93% | 83% |
| Accuracy | 96% (PPA) | 96% (PPA) |
| 97% (PPV) | 96% (PPV) | |
| LOD (Limit Of Detection) |
0.25% VAF (L858R : 0.5% VAF) |
0.25% |
Library preparation process
